RNA polymerase II associated protein 2Genealiases: C1orf82 · Rtr1
Q-omics provides the consensus-scored RPAP2 profile across patient tissues and cancer cell-line models. RPAP2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPAP2 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, RPAP2 RNA expression shows 21,003 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where RPAP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPAP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPAP2 survival associations across molecular data types. RPAP2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPAP2 RNA expression–survival associations across cancer types. High RPAP2 expression shows unfavorable associations in ACC, LIHC, KICH and LGG, but favorable associations in KIRC and GBM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPAP2 RNA expression.
This table summarizes RPAP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPAP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPAP2 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, LUAD and LUSC. The THCA box plot shows higher RPAP2 RNA expression in normal versus tumor tissue (log2 FC = −0.917, t-test p < 0.001).
This table shows molecular features associated with RPAP2 in patient tissues and cancer cell lines. In patient samples, RPAP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPAP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
